touchNEUROLOGY caught up with Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) one of our Editorial Board Members, to discuss BAN2401’s use in early stage Alzheimer’s Disease, and Amyloid Related Imaging Abnormalities (ARIA)-E alterations and their utility in amyloid-modifying trials.
The abstract entitled: ‘Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings Over 12 Months Of Treatment In The Open-Label Extension Of The Phase 2b Study BAN2401-G000-201 In Subjects With Early Alzheimer’s Disease’ was presented in relation to this interview, at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- What is known about the role of Amyloid beta protofibrils in the pathophysiology of Alzheimer’s Disease? (0:18)
- What is BAN2401 and what clinical evidence supports its use in early stage Alzheimer’s Disease? (1:36)
- Could you tell us a little about Amyloid Related Imaging Abnormalities (ARIA)-E alterations and their utility in amyloid-modifying trials? (2:49)
Disclosures:
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
